Navigation Links
Neuralstem CEO To Present At Stem Cells & Regenerative Medicine Congress
Date:9/26/2013

hemic stroke. The company has received FDA approval to commence a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company is conducting a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include traumatic brain injury (TBI), Alzheimer's disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter, Facebook and LinkedIn

Cautionary Statement Regarding Forward Looking Information 

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forw
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neuralstem Updates ALS Stem Cell Trial Progress
2. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
3. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
4. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
5. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
6. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
7. Neuralstem Announces Proposed Public Offering
8. Neuralstem to Raise $7.0 Million in Registered Direct Offering
9. Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2013
10. Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center
11. Neuralstem Secures $8 Million In Debt Financing From Hercules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... report to their offering. ... hollow needle commonly used with a syringe to inject ... from it. A hypodermic needle is used for rapid ... be ingested. Hypodermic needles are broadly classified into non-safety ...
(Date:7/11/2014)... , July 11, 2014 ... at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished ... closed at 1,964.68, down 0.41%. The losses were broad based ... negative. The S&P 500 Health Care Sector Index ended the ... 2.75% in the last one month. Investor-Edge has initiated coverage ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Veran Medical Publishes Lung Cancer Patient Management Study 2
... 4, 2011 Reportlinker.com announces that a new ... European Market for Cardiac Rhythm ... http://www.reportlinker.com/p0488652/European-Market-for-Cardiac-Rhythm-Management-Electrophysiology--Ablation-Devices-2011.html European Market ... 2011 (15 countries) In 2010, ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... – Bone Grafting and Hyaluronic Acid ... http://www.reportlinker.com/p0488653/European-Markets-for-Orthopedic-Biomaterials-2011-–-Bone-Grafting-and-Hyaluronic-Acid-Viscosupplementation-15-Countries.html The ...
Cached Medicine Technology:Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 2Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 3Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 4Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 5Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 6Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 7Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 8Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 9Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 10Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 11Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 12Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 13Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 14Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 15Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 16Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 17Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 18Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 19Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 20Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 21Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 2Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 3Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 4Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 5Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 6Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 7Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 8Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 9Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 10Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 11Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 12Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 13Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 14Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 15Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 16
(Date:7/13/2014)... By Serena Gordon ... -- A new type of sensor for people with ... body using saliva instead of blood, researchers report. Scientists ... successfully tested it using artificial saliva. It uses light, metal ... blood sugar. "Everybody knows that diabetics have to prick ...
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special occasion dress manufacturer ... gorgeous Quinceanera dresses . , In ... outfits is huge. Therefore, 2014QuinceaneraDresses.com is striving to ... released dresses are made according to the latest ... , It is worthy of mention that ...
(Date:7/13/2014)... 13, 2014 Epidemiologists forecast an increase ... 6MM, from 8,062 diagnosed incident cases in 2013 to ... Growth Rate (AGR) of 4.35%, during the forecast period. ... of diagnosed incident cases of aGVHD in the 6MM, ... the lowest number of diagnosed incident cases of aGVHD, ...
(Date:7/13/2014)... 13, 2014 Wright & Schulte LLC ... been scheduled in July of 2015, in U.S. District ... are in the discovery process in the South ... is presiding over the multidistrict litigation (MDL). The complaints ... of individuals who allege that they took the statin ...
(Date:7/13/2014)... 2014 Hope Palliative & Hospice Care announced ... group at the Tamarack Senior Living Community in Palatine, IL. ... A.M. on the 3rd Wednesdays of every month. This ... Tamarack Community located at 55 S. Greeley St. Palatine, IL ... there is no cost for the group. , “A ...
Breaking Medicine News(10 mins):Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
... drug to the usual three-drug HIV treatment regimen is not ... the HIV load// or the drug resistance, the new study ... JAMA, a theme issue on HIV/AIDS. ,Roy M. ... New York, presented the findings of the study today at ...
... used HIV treatments, researchers found one triple-drug therapy was ... the blood when used as a first-line treatment. Results ... among three different therapies the optimal approach for patients ... reported at the XVI International AIDS Conference (AIDS 2006). ...
... new study published in the September 15, 2006 issue ... Society, says that African-Americans are least likely to// ask ... says that the level of interest displayed by Caucasian ... This fact may lead to the African-Americans making less-informed ...
... has said that better quality drugs and child medication ... ,Speaking to Agence France-Presse (AFP) ... in Toronto he said, "We definitely need to improve ... talking to pharmaceuticals. We definitely want to buy second-line ...
... radical changes in business with tangible growth in Asian countries, ... of a jet setting pace, so much a part of ... a demographic crisis, with a rampant spread of mental health ... palpable, and is attributed to the high stress in the ...
... in on a weakened scout cell, which is known to ... out that cancer in some of the transplant patients shows ... for the immune system. Researchers are optimistic that by ... find ways to prevent the onset of cancer. The reason ...
Cached Medicine News:Health News:Four-Drug AIDS Treatment Regimen Deemed Of No Use 2Health News:Study Compares First-Line Drug Therapies For Treating HIV 2Health News:Study Compares First-Line Drug Therapies For Treating HIV 3Health News:Study Compares First-Line Drug Therapies For Treating HIV 4Health News:African-Americans Pose Less Questions To Treating Doctors 2Health News:Need for Newer AIDS Drugs In China 2
Smaller diameter wire probes & olive shape tips provide easier insertion through the lacrimal sac, 35cm (14 in) long, ID- .30mm (.012in); OD- .64mm (.025 in). S.S. Probes: .40mm x 11cm (27 G x 4 1/4...
...
Pre-set guard for precise depth incision, bi-directional blade can cut left or right. 250 micron....
Universal, clear, lightweight plastic with smooth edges & ventilation holes for patient comfort...
Medicine Products: